All stories tagged :

Pr Newswire

4DMT to Participate in Chardan’s 9th Annual Genetic Medicines Conference

Tháng 10 14

Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its...

1 năm ago

ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with...

1 năm ago

Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among...

1 năm ago

SLB and Aker Carbon Capture announce closing of carbon capture joint...

1 năm ago

Waydoo Flyer EVO: The Future of Efoiling

1 năm ago

THE HO CHI MINH CITY RIVER FESTIVAL 2024: UNFORGETTABLE AND INSPIRING...

1 năm ago

Bybit Web3 Celebrates 10 Million Wallet Milestones and Unveils Giveaways Worth...

1 năm ago

DobaShare Brings Excitement to Back-to-School Shopping with High-Commission Offers

1 năm ago

Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising...

1 năm ago

Vaxart Announces $40 Million Underwritten Offering of Common Stock

1 năm ago

1 2 3 … 751 752 753 754 755 756 757 … 761 762 763 Page 754 of 763

Featured

Opus Genetics to Participate in Chardan’s 9th Annual Genetic Medicines Conference

10 giờ ago

Hawx Services Celebrates Serving 14 States Across Nationwide

10 giờ ago

AICB Launches FSF Xcel: Malaysia’s First Industry-Wide Skills Assessment Platform to...

10 giờ ago

Morgan Stanley Raises JOYY (JOYY.US) Target Price from US$40 to US$62...

10 giờ ago

10 giờ ago

Opus Genetics to Participate in Chardan’s 9th Annual Genetic Medicines Conference

RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, announced today that Ash...